UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/506,819	04/19/2005	Masayuki Kawakami	LEDER-0010	5431
	7590 10/18/2007 ITE, ZELANO & BRAN	EXAMINER		
2200 CLARENDON BLVD.			JONES, DAMERON LEVEST	
SUITE 1400 ARLINGTON, VA 22201		ART UNIT	PAPER NUMBER	
			1618	
			MAIL DATE	DELIVERY MODE
			10/18/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)				
Office Action Summary		10/506,819	KAWAKAMI ET AL.				
		Examiner	Art Unit				
		D. L. Jones	1618				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SH WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory period we are to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
	Responsive to communication(s) filed on 26 July 2007.						
-	☐ This action is FINAL . 2b)☐ This action is non-final.						
3)∟	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims						
5)□ 6)⊠ 7)⊠	Claim(s) 1,2,4,5 and 8-13 is/are pending in the 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 1,2,4,5,9 and 10 is/are rejected. Claim(s) 8 and 11-13 is/are objected to. Claim(s) are subject to restriction and/or	vn from consideration.					
Applicat	ion Papers						
9)☐ The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11)	Replacement drawing sheet(s) including the correcting The oath or declaration is objected to by the Example 1.	• • • • •					
Priority (under 35 U.S.C. § 119						
12) a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of: Certified copies of the priority documents Certified copies of the priority documents Copies of the certified copies of the prioric application from the International Bureau See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachmen							
2) Notic 3) Infor	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa	te				

ACKNOWLEDGMENT

1. The Examiner acknowledges receipt of the amendment filed 7/26/07 wherein claims 1, 4, and 9-11 were amended; claims 3, 6, and 7 were canceled; and claims 12 and 13 were added.

Note: claims 1, 2, 4, 5, and 8-13 are pending.

RESPONSE TO APPLICANT'S AMENDMENT/ARGUMENTS

2. The Applicant's arguments and/or amendment filed 7/26/07 to the rejection of the claims made by the Examiner under 35 USC 103, 112, and/or double patenting have been fully considered and deemed persuasive-in-part for the reasons set forth below.

Double Patenting Rejections

The rejection of claims 1, 2, 4, and 5 on the ground of non-statutory obviousness-type double patenting as being unpatentable over claims 1-8 of US Patent No. 6,939,975 is MAINTAINED for reasons of record in the office action mailed 2/26/07 and those set forth below.

Applicant asserts that the double patenting rejection must be withdrawn because the patented claims are directed to compounds and the claims of the instant invention are drawn to diagnostic contrast agents suitable for near infrared fluorescent imaging and corresponding methods thereof.

Applicant's arguments are non-persuasive because both sets of claims are directed to compounds having the same components. Furthermore, if the product components are the same and a product is inseparable from its properties, then if the claims of the instant invention are useful as a diagnostic agent, then so are the patented

Application/Control Number: 10/506,819 Page 3

Art Unit: 1618

products. In addition, it is noted that while Applicant asserts that the instant invention is useful as a diagnostic agent, the claims do not require the presents of a detectable isotope. Thus, the claims contain overlapping subject matter and the double patenting rejection is deemed proper.

112 Second Paragraph Rejections

I. The rejection of claims 1-11 as being ambiguous because of the wording of claim 1 is WITHDRAWN because Applicant has amended the claims to overcome the rejection

II. The rejection of claim 1 under 35 USC 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicant regards as the invention is MAINTAINED.

In particular, the rejection of claim 1, lines 9-10, as being confusing because it states that R3, R4, R5, R6, R9, R10, R11, and R12 bind to each other to form a ring is MAINTAINED for reasons of record in the office action mailed 2/26/07 and those set forth below. Once again, the variable all do not bind to one another to form a ring. It is groups of twos (i.e., R3 and R4) that bind to form a ring. Thus, Applicant is once again respectfully requested to clarify the claims in order that one may readily ascertain what is being claimed.

Note: It is duly noted that Applicant did not respond to the Examiner's rejection in the response.

III. The rejection of claim 1, line 18, is WITHDRAWN because Applicant has amended the claim to overcome the rejection.

Art Unit: 1618

IV. The rejection of claims 9 and 10 under 35 USC 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicant regards as the invention is MAINTAINED.

In particular, it was previously stated that the claims are not further limiting. The Examiner asked if Applicant intended to write 'A method of tumor imaging...'. The claims do not further limiting the contrast agent of claim 1 because a product claim is limited by further defining its component, not by incorporating the intended use of the contrast agent.

Note: While Applicant amended claims 9 and 10 to state that the contrast agents are adapted for a particular use, it is noted that the amending of the claims does not further limit the components of the product.

103 Rejections

The 103 rejections are WITHDRAWN because Applicant has amended the claims to overcome the rejections.

COMMENTS/NOTES

- 3. Applicant is respectfully requested to replace 'A' with 'The' in claims 12 and 13.
- 4. It is duly noted that no prior art is cited against the instant claims. However, Applicant MUST address and overcome the double patenting rejection above. The claims are distinguished over the prior art of record because the prior art neither anticipates nor renders obvious the contrast agents of the instant invention or uses

Application/Control Number: 10/506,819

Art Unit: 1618

thereof. The closest art is Applicant's own work that is cited in the double patenting rejection above.

5. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. L. Jones whose telephone number is (571) 272-0617. The examiner can normally be reached on Mon.-Fri., 6:45 a.m. - 3:15 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

Art Unit: 1618

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

D. L. Jones
Primary Examiner
Art Unit 1618

October 10, 2007